2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 1946

Development of a Multi-Component 3D Arthritic Joint Model

Biology and Pathology of Bone and Joint Poster II

9:00AM-11:00AM: Abstract Number: 2659

Development of a Protocol for Single Cell Transcriptomics of Cells from Cryopreserved Lupus Nephritis Kidney Tissue and Urine for the Accelerating Medicines Partnership RA/SLE Network

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2022

Diagnostic and Prognostic VALUE of Salivary GLAND Ultrasonography in Primary Sjögren’s Syndrome: a Preliminary Study

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2023

Diagnostic Value of the Non-Observation of the Frontal Branch of the Temporal Arteries By Ultrasonography in the Diagnostic of Giant Cell Arteritis (GCA)

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1953

Dietary Quality and Risk of SLE in the Nurses’ Health Studies

Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

9:00AM-11:00AM: Abstract Number: 2394

Differential Effect of Corticosteroids and Biological Dmards on Five-Year Radiographic Progression in Rheumatoid Arthritis: Results from a Weighted Cumulative Exposure Model Developed on the Espoir Cohort

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2726

Differentiating Features of Primary Angiitis of Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome: Clinical and Radiological Evaluation

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 1939

Dipyridamole, an Ent-1 Adenosine Transporter Inhibitor, Reverts De Osteoclastic Phenotype Induced By Tenofovir

Biology and Pathology of Bone and Joint Poster II

9:00AM-11:00AM: Abstract Number: 2254

Disability (HAQ) and Quality of Life (SF-12) As Related to Adherence and Health Literacyin Patients with Rheumatoid Arthritis – the Trace-Study

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2234

Disability in Acute Low Back Pain: The Role of Pain Severity, Pain Catastrophizing, Depression, and Exercise

ARHP Pain – Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 2554

Disease Activity in Psoriatic Arthritis-ESR Index Maybe a Valid Tool to Evaluate Disease Activity in Patients with Psoriatic Arthritis When CRP Is Not Available

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2456

Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

9:00AM-11:00AM: Abstract Number: 2356

Disease Severity Impacts the Relationships of Apelin Concentrations with Arterial Function in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2612

Disparities in Antimalarial Prescribing for Systemic Lupus Erythematosus Using a Real-World, Electronic Health Record

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2168

Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis

Muscle Biology, Myositis and Myopathies Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].